S
Surendra S. Ambegaokar
Researcher at Ohio Wesleyan University
Publications - 23
Citations - 3396
Surendra S. Ambegaokar is an academic researcher from Ohio Wesleyan University. The author has contributed to research in topics: Kinase & Neurodegeneration. The author has an hindex of 14, co-authored 23 publications receiving 3076 citations. Previous affiliations of Surendra S. Ambegaokar include University of California, Berkeley & University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo
Fusheng Yang,Giselle P. Lim,Giselle P. Lim,Aynun N. Begum,Aynun N. Begum,Oliver J. Ubeda,Oliver J. Ubeda,Mychica Simmons,Mychica Simmons,Surendra S. Ambegaokar,Surendra S. Ambegaokar,Pingping P. Chen,Pingping P. Chen,Rakez Kayed,Charles G. Glabe,Sally A. Frautschy,Sally A. Frautschy,Gregory M. Cole,Gregory M. Cole +18 more
TL;DR: It is suggested that low dose curcumin effectively disaggregates Aβ as well as prevents fibril and oligomer formation, supporting the rationale forCurcumin use in clinical trials preventing or treating AD.
Journal ArticleDOI
Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease.
Lixia Zhao,Qiu-Lan Ma,Qiu-Lan Ma,Frédéric Calon,Marni E. Harris-White,Marni E. Harris-White,Fusheng Yang,Fusheng Yang,Giselle P. Lim,Giselle P. Lim,Takashi Morihara,Oliver J. Ubeda,Oliver J. Ubeda,Surendra S. Ambegaokar,Surendra S. Ambegaokar,James E. Hansen,James E. Hansen,Richard H. Weisbart,Richard H. Weisbart,Bruce Teter,Bruce Teter,Sally A. Frautschy,Greg M. Cole +22 more
TL;DR: It is shown that PAK and its activity are markedly reduced in Alzheimer disease and that this is accompanied by reduced and redistributed phosphoPAK, prominent cofilin pathology and downstream loss of the spine actin-regulatory protein drebrin, which cofilIn removes from actin.
Journal ArticleDOI
Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention.
Lixia Zhao,Bruce Teter,Takashi Morihara,Giselle P. Lim,Surendra S. Ambegaokar,Oliver J. Ubeda,Sally A. Frautschy,Greg M. Cole +7 more
TL;DR: In vitro and in vivo analyses validate the use of enhanced CNS insulin signaling as a potential strategy for AD intervention to correct the IDE defects occurring in AD.
Journal ArticleDOI
Antibodies against β‐amyloid reduce aβ oligomers, glycogen synthase kinase‐3β activation and τ phosphorylation in vivo and in vitro
Qiu-Lan Ma,Giselle P. Lim,Giselle P. Lim,Marni E. Harris-White,Marni E. Harris-White,Fusheng Yang,Fusheng Yang,Surendra S. Ambegaokar,Surendra S. Ambegaokar,Oliver J. Ubeda,Oliver J. Ubeda,Charles G. Glabe,Bruce Teter,Bruce Teter,Sally A. Frautschy,Sally A. Frautschy,Greg M. Cole +16 more
TL;DR: In this article, active and passive immunization against the beta-amyloid peptide (Abeta) of amyloid plaque-bearing transgenic mice markedly reduced plaque deposition and improved cognition, the mechanisms of neuroprotection and impact on toxic oligomer species are not understood.
Journal ArticleDOI
Functional genomic screen and network analysis reveal novel modifiers of tauopathy dissociated from tau phosphorylation
TL;DR: 37 additional genes identified from ∼1900 genes screened, including the kinases shaggy/GSK-3beta, par-1/MARK, CamKI and Mekk1 are reported, suggesting that tau can participate in signaling pathways to regulate its own kinases and suggest therapeutic targets other than mitigation of tau phosphorylation.